A Senate plan to tackle patient cost-sharing for insulin is estimated to increase the federal deficit by $23.3 bn over a decade, about double the impact of the insulin-provisions in a similar House bill.
The difference is largely due to pharma-friendly elements of the Senate bill that would among other things increase the average...